U.S. Markets close in 1 hr 24 mins

Solid Biosciences Inc. (SLDB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.8950+0.3450 (+9.72%)
As of 2:35PM EDT. Market open.

Solid Biosciences Inc.

141 Portland Street
Fifth Floor
Cambridge, MA 02139
United States
617 337 4680

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees70

Key Executives

NameTitlePayExercisedYear Born
Mr. Ilan GanotCo-founder, Pres, CEO & Director829.25kN/A1974
Mr. Matthew Bennett ArnoldCo-Founder & Independent Director42.5kN/A1970
Dr. Carl Ashley MorrisChief Scientific Officer547.4kN/A1970
Ms. Annie GanotCo-Founder & Director of Patient AdvocacyN/AN/AN/A
Mr. Stephen J. DiPalma M.B.A.Interim CFO, Treasurer & Principal Accounting OfficerN/AN/A1959
Dr. Joel Solomon Zev SchneiderChief Operating OfficerN/AN/A1985
Mr. Geoffrey M. GrandeVP & Head of Investor RelationsN/AN/AN/A
Ms. Erin Powers BrennanChief Legal Officer & Sec.N/AN/A1971
Mr. Tim PalmerCorp. Communications Mang.N/AN/AN/A
Dr. Cathryn M. Clary M.B.A., M.D.Acting Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Solid Biosciences Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.